ProVise Management Group LLC Sells 11,304 Shares of GSK plc (NYSE:GSK)

ProVise Management Group LLC lowered its stake in shares of GSK plc (NYSE:GSK - Free Report) by 9.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,051 shares of the pharmaceutical company's stock after selling 11,304 shares during the period. ProVise Management Group LLC's holdings in GSK were worth $3,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Horizon Investments LLC raised its position in shares of GSK by 2.7% during the fourth quarter. Horizon Investments LLC now owns 17,206 shares of the pharmaceutical company's stock valued at $582,000 after buying an additional 455 shares during the last quarter. Primecap Management Co. CA raised its position in shares of GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after buying an additional 10,407,905 shares during the last quarter. Argent Advisors Inc. grew its holdings in shares of GSK by 9.6% in the fourth quarter. Argent Advisors Inc. now owns 32,657 shares of the pharmaceutical company's stock valued at $1,104,000 after purchasing an additional 2,847 shares in the last quarter. Tocqueville Asset Management L.P. grew its holdings in shares of GSK by 23.6% in the fourth quarter. Tocqueville Asset Management L.P. now owns 46,900 shares of the pharmaceutical company's stock valued at $1,586,000 after purchasing an additional 8,950 shares in the last quarter. Finally, Horizon Kinetics Asset Management LLC grew its holdings in shares of GSK by 4.4% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 39,865 shares of the pharmaceutical company's stock valued at $1,348,000 after purchasing an additional 1,673 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Trading Down 0.5 %

NYSE GSK traded down $0.19 on Friday, hitting $39.22. 4,020,576 shares of the stock were exchanged, compared to its average volume of 4,345,710. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The stock has a fifty day moving average price of $36.66 and a two-hundred day moving average price of $36.92. The firm has a market capitalization of $81.18 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.01%. This is an increase from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. GSK's dividend payout ratio (DPR) is 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.